T2-FLAIR Mismatch Sign and Response to Radiotherapy in Diffuse Intrinsic Pontine Glioma.


Journal

Pediatric neurosurgery
ISSN: 1423-0305
Titre abrégé: Pediatr Neurosurg
Pays: Switzerland
ID NLM: 9114967

Informations de publication

Date de publication:
2021
Historique:
received: 02 06 2020
accepted: 23 11 2020
pubmed: 4 2 2021
medline: 29 10 2021
entrez: 3 2 2021
Statut: ppublish

Résumé

The T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign was previously reported as a diagnostic indicator of diffuse astrocytoma, isocitrate dehydrogenase-mutant, and 1p/19q noncodeletion. Subsequently, it was reported that the same findings were observed in diffuse intrinsic pontine glioma (DIPG). We investigated the clinical significance of T2-FLAIR mismatch sign in DIPG. Twenty-one patients with DIPG (Male: Female = 12:9) were treated at our institute between 2004 and 2019. All patients were treated with local radiotherapy of 54 Gy/30 fractions. The positive T2-FLAIR mismatch sign was defined if it fulfilled the following criteria: (1) T2-FLAIR mismatch volume was >50% of T2 high volume at nonenhanced area, (2) the FLAIR low lesion is not associated with gadolinium enhancement (inside of enhancement or just outside of enhancement defined as edema), and (3) signal-intensity of FLAIR lowest lesion at tumor is lower than the normal cerebellar cortex. In our patient series, T2-FLAIR mismatch sign was found in 5 out of 21 patients. Objective response rate of radiotherapy was 100% in patients positive for T2-FLAIR mismatch, while it was 25.0% in patients negative for T2-FLAIR mismatch, and this difference was statistically significant (p < 0.01, Fisher's exact test). In patients under the age of 18-years, T2-FLAIR mismatch positive had a slightly better prognosis (p < 0.05, Wilcoxon test). T2-FLAIR mismatch sign in DIPG may be an indicator for better response to radiotherapy and a better prognostic factor.

Identifiants

pubmed: 33535215
pii: 000513360
doi: 10.1159/000513360
doi:

Substances chimiques

Contrast Media 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Fumiyuki Yamasaki (F)

Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan, fyama@hiroshima-u.ac.jp.

Ikuno Nishibuchi (I)

Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan.

Shuhei Karakawa (S)

Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.

Yoko Kaichi (Y)

Department of Diagnostic Radiology, Hiroshima University Hospital, Hiroshima, Japan.

Manish Kolakshyapati (M)

Department of Neurosurgery, B&B Hospital, Gwarko, Lalitpur, Nepal.

Motoki Takano (M)

Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan.

Ushio Yonezawa (U)

Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan.

Nobuki Imano (N)

Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan.

Akira Taguchi (A)

Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan.

Maiko Shimomura (M)

Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.

Maki Taniguchi (M)

Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.

Shumpei Onishi (S)

Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan.

Satoshi Okada (S)

Department of Pediatrics, Hiroshima University Hospital, Hiroshima, Japan.

Kazuo Awai (K)

Department of Diagnostic Radiology, Hiroshima University Hospital, Hiroshima, Japan.

Kazuhiko Sugiyama (K)

Department of Clinical Oncology and Neuro-Oncology Program, Hiroshima University Hospital, Hiroshima, Japan.

Yasushi Nagata (Y)

Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH